Daniel J DeAngelo
Overview
Explore the profile of Daniel J DeAngelo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
284
Citations
12094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Su W, Stricherz M, Martin A, Belsey J, Kemadjou E, DeAngelo D
Am J Hematol
. 2025 Feb;
PMID: 39945071
Adults with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) have poorer outcomes than pediatric patients. The aim of this systematic literature review and meta-analysis was to compare asparaginase (ASP)-containing pediatric-inspired regimens (PIRs)...
2.
Short N, Aldoss I, DeAngelo D, Konopleva M, Konopleva M, Leonard J, et al.
Blood Adv
. 2025 Jan;
PMID: 39853316
Measurable residual disease (MRD) is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia (ALL). In addition to its clear prognostic importance, MRD information is increasingly used in clinical...
3.
Aldoss I, Roboz G, Bassan R, Boissel N, DeAngelo D, Fleming S, et al.
Lancet Haematol
. 2024 Dec;
11(12):e959-e970.
PMID: 39638543
In the past decade, there has been considerable progress in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia. This evolution is the product of a more profound...
4.
Roddie C, Sandhu K, Tholouli E, Logan A, Shaughnessy P, Barba P, et al.
N Engl J Med
. 2024 Nov;
391(23):2219-2230.
PMID: 39602653
Background: Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence. Methods: We conducted...
5.
Luskin M, Shimony S, Keating J, Keating J, Winer E, Garcia J, et al.
Blood Adv
. 2024 Nov;
9(3):617-626.
PMID: 39546748
In acute lymphoblastic leukemia (ALL), the B-cell lymphoma 2 inhibitor venetoclax may enhance the efficacy of chemotherapy, allowing dose reductions. This phase 1b study of venetoclax plus attenuated chemotherapy enrolled...
6.
Shimony S, Raman H, Flamand Y, Keating J, Paolino J, Valtis Y, et al.
Blood Cancer J
. 2024 Nov;
14(1):191.
PMID: 39482298
Asparaginase (ASP)-containing regimens for acute lymphoblastic leukemia (ALL) are associated with venous thromboembolism (VTE). We evaluated the prevalence, risk factors, role of prophylaxis and clinical impact of VTE among adolescents...
7.
Shah B, Mattison R, Abboud R, Abdelmessieh P, Aldoss I, Burke P, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):563-576.
PMID: 39413812
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based...
8.
Luskin M, Murakami M, Murakami M, Keating J, Keating J, Flamand Y, et al.
Blood
. 2024 Oct;
145(6):577-589.
PMID: 39374521
Dasatinib is an effective treatment for Philadelphia chromosome-positive (Ph+) acute leukemia, but some patients develop resistance. Combination treatment with dasatinib and asciminib, an allosteric inhibitor of BCR::ABL1, may deepen responses...
9.
Bleyer A, Tai E, Siegel S, Roth M, DeAngelo D, Stock W
J Adolesc Young Adult Oncol
. 2024 Sep;
PMID: 39321033
In 2018, a "survival cliff" in the United States was identified among older adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). This study...
10.
Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, et al.
Blood Adv
. 2024 Sep;
8(23):6043-6054.
PMID: 39293089
Approximately 25% of patients with essential thrombocythemia (ET) present with extreme thrombocytosis (ExT), defined as having a platelet count ≥1000 × 109/L. ExT patients may have an increased bleeding risk...